Residual Mass in Aggressive Lymphoma - Does Size, Measured by Computed Tomography, Influence Clinical Outcome?

References

• Shipp MA, Mauch PM, Harris N. Non-Hodgkin's lymphoma. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer. 'Principles and practice of oncology. 5th ed. Philadel-phia, Pennsylvania: JB Lippincott & Co, 1997.
   Google Scholar
• Bremnes RM, Bremnes Y, Donnem T. High-grade non-Hodgkin's lymphoma treated in northern Norway. Treat-ment, outcome and prognostic factors. Acta Oncol 1999; 38: 117–24.
   Google Scholar
• Canellos GP. Residual mass in lymphoma may not be resid-ual disease. J Clin Oncol 1988; 6: 931–3.
   PubMed Web of Science ®Google Scholar
• Lewis E, Bernardino ME, Salvador PG, et al. Post-therapy CT-detected mass in lymphoma patients: is it viable tissue? J Comput Assist Tomogr 1982; 6: 792–5.
   PubMed Web of Science ®Google Scholar
• Steward FM, Williamson BR, Innes DJ, et al. Residual tumour masses following treatment for advanced histocyticlymphoma. Diagnostic and therapeutic implications. Cancer 1985; 55: 620–3.
   Google Scholar
• Surbone A, Longo D, De Vita V, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combi-nation chemotherapy: significance and management. J Clin Oncol 1988; 6: 1832–7.
   PubMed Web of Science ®Google Scholar
• Canini R, Battista G, Monetti N, et al. Bulky mediastinal lymphomas: magnetic resonance imaging and gallium scan in the management of residual masses. Radiol Med 1995; 90: 448–56.
   PubMedGoogle Scholar
• Jerkeman M, Anderson H, Cavallin-Stahl E, et al. CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomized trial. Ann Oncol 1999; 10: 1079–86.
   Google Scholar
• Stansfeld A, Diebold J, Kapanci Y et al. Updated Kiel classification for lymphomas., Lancet 1988; 292–293.
   Google Scholar
• Harris NL, Jaffe ES, Stein H. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–92.
   Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee in Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860–1.
   PubMed Web of Science ®Google Scholar
• Nyman R, Rehn S, Glimelius B, et al. Residual mediastinal masses in Hodgkin's disease: prediction of size with MR imaging. Radiology 1989; 170: 435–40.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD, Hutchins M, et al. Chemotherapy for diffuse large cell lymphoma: rapidly re-sponding patients have more durable remissions. J Clin Oncol 1986; 4: 160–4.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Zompatori M, Bendandi M, et al. Monitoring bulky mediastinal disease with gallium-67 CT scan and mag-netic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymph 1996; 22: 131–5.
   PubMed Web of Science ®Google Scholar
• Hill M, Cunningham D, MacVicar D, et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 1993; 11: 2273–8.
   PubMed Web of Science ®Google Scholar
• Janicek M, Kaplan W, Neuberg D, et al. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15: 1631–7.
   PubMed Web of Science ®Google Scholar
• Brice P, Rain JD, Frija J, et al. Residual mediastinal mass in malignant lymphoma: value of magnetic resonance imaging and gallium scan. Nouv Rev Fr Hematol 1993; 35: 457–61.
   PubMedGoogle Scholar
• Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-(F-18)-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111–6.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Magagnoli M, Chierichetti, et al. The role of positron emission tomography (PET) in the management of lymphoma patients., Ann Oncol 1999; 10: 1181–84.
   PubMed Web of Science ®Google Scholar
• Bangerter M, Kotzerke J, Griesshammer M, et al. Positron emission tomography with 18-fluorodeoxyglucose in the stag-ing and follow-up of lymphoma in the chest. Acta Oncol 1999; 38: 799–804.
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using F-18-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429–33.
   PubMed Web of Science ®Google Scholar
• Horwich A, Paluchowska B, Norman A, et al. Residual mass following chemotherapy of seminoma. Ann Oncol 1997; 8: 37–40.
   PubMed Web of Science ®Google Scholar
• Inane SE, Meral R, Darendeliter E, et al. Prognostic signifi-cance of marker half-life during chemotherapy in non-semi-nomatous germ cell testicular tumours. Acta Oncol 1999; 38: 505–9.
   PubMed Web of Science ®Google Scholar